Search Results Search Sort by RelevanceMost Recent In the Literature Jun 2007 Cosmetic Psychopharmacology and the Goals of Medicine Erica K. Rangel A look at Pamela Bjorkland’s critique of the use of psychoactive drugs to improve mood, a practice known as cosmetic psychopharmacology. Virtual Mentor. 2007;9(6):428-432. doi: 10.1001/virtualmentor.2007.9.6.jdsc1-0706. Case and Commentary Apr 2016 Prenatal Risk Assessment and Diagnosis of Down Syndrome: Strategies for Communicating Well with Patients Eva Schwartz, MD and Kishore Vellody, MD Physicians should provide women considering abortion after Down syndrome screening with unbiased information and not attempt to influence their decision. AMA J Ethics. 2016;18(4):359-364. doi: 10.1001/journalofethics.2016.18.4.ecas1-1604. Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 1 Stephen L. Brotherton, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):298-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 2 Norman C. Fost, MD, MPH Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):300-301. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 3 Gary A. Green, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):301-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. State of the Art and Science Dec 2016 Locating Risk in the Adolescent Brain: Ethical Challenges in the Use of Biomarkers for Adolescent Health and Social Policy Suparna Choudhury, PhD and Sheehan Moore Neurobiological markers raise complex questions about what it means to be “at risk.” AMA J Ethics. 2016;18(12):1199-1206. doi: 10.1001/journalofethics.2016.18.12.stas1-1612.
In the Literature Jun 2007 Cosmetic Psychopharmacology and the Goals of Medicine Erica K. Rangel A look at Pamela Bjorkland’s critique of the use of psychoactive drugs to improve mood, a practice known as cosmetic psychopharmacology. Virtual Mentor. 2007;9(6):428-432. doi: 10.1001/virtualmentor.2007.9.6.jdsc1-0706.
Case and Commentary Apr 2016 Prenatal Risk Assessment and Diagnosis of Down Syndrome: Strategies for Communicating Well with Patients Eva Schwartz, MD and Kishore Vellody, MD Physicians should provide women considering abortion after Down syndrome screening with unbiased information and not attempt to influence their decision. AMA J Ethics. 2016;18(4):359-364. doi: 10.1001/journalofethics.2016.18.4.ecas1-1604.
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 1 Stephen L. Brotherton, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):298-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 2 Norman C. Fost, MD, MPH Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):300-301. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 3 Gary A. Green, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):301-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
State of the Art and Science Dec 2016 Locating Risk in the Adolescent Brain: Ethical Challenges in the Use of Biomarkers for Adolescent Health and Social Policy Suparna Choudhury, PhD and Sheehan Moore Neurobiological markers raise complex questions about what it means to be “at risk.” AMA J Ethics. 2016;18(12):1199-1206. doi: 10.1001/journalofethics.2016.18.12.stas1-1612.
